TrialReviews on recent clinical trials2025

Empagliflozin Ameliorates the Oxidative Stress Profile in Type 2 Diabetic Patients with Heart Failure and Reduced Ejection Fraction: Results of a Randomized, Double-blind, Placebo-controlled Study.

Azadeh Eshraghi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.